By analyzing medical records of 901 adults who had surgery for a certain type of precancerous pancreatic cyst, researchers at Johns Hopkins Medicine and Karolinska Institute in Sweden have updated parameters for an anatomical “marker” that can tell more precisely if these cysts are likely to develop into lethal pancreatic cancers.
Bristol-Myers Squibb Co. said the phase III CheckMate-498 trial evaluating Opdivo (nivolumab) plus radiation vs. temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.
City of Hope is enrolling patients with multiple myeloma whose disease has relapsed, or is treatment-resistant, for a first-of-its kind chimeric antigen receptor T-cell therapy trial.
A new study by American Cancer Society researchers finds medical financial hardship is common among people in the U.S., with more than half reporting problems with affordability, stress, or delaying care because of cost.
A team of researchers at UCLA's Jonsson Comprehensive Cancer Center, Cedars-Sinai Cancer, and Dana-Farber Cancer Institute have newly identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer.
A breast cancer test has been found that helps doctors make treatment decisions for some breast cancer patients, following research carried out at Queen Mary University of London and funded by Cancer Research UK.
Myriad Genetics Inc. announced an international team of cancer researchers has found EndoPredict test accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy. Findings from the study were published in the journal, Breast Cancer Research and Treatment.
Using next-generation sequencing based RNA-sequencing, researchers at Fox Chase Cancer Center found a fusion gene signature in primary tracheobronchial adenoid cystic carcinoma, a rare lung tumor. This study is the first time the MYB/MYBL1 fusion genes have been systemically investigated for this cancer type.
Research by Marwan Fakih, a City of Hope physician-scientist, could help metastatic colorectal cancer patients decide whether to choose immunotherapy or chemotherapy as their first treatment option.
Inivata conducted two prospective, multi-center studies in collaboration with 41 key institutions across the United States. The data, published in JCO Precision Oncology, highlights the potential of Inivata's first Medicare-reimbursed commercial test to improve delivery of comprehensive tumor genomic profiling.
